Mario Annunziata

7PUBLICATIONS
63CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 05, 2025
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.

Roberta Della Pepa, Salvatore Palmieri, Stefano Rocco

|May 07, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

Michael J Mauro, Yosuke Minami, Andreas Hochhaus

|Feb 26, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.

Renato Bassan, Sabina Chiaretti, Irene Della Starza

|Sep 28, 2023
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.

Nicola Stefano Fracchiolla, Mariarita Sciumè, Cristina Papayannidis

|Aug 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Delphine Réa, Michael J Mauro, Carla Boquimpani

|Jul 23, 2021
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine

Pageof 2

Frequent Collaborators

2 joint publications

Sergey Voloshin

2 joint publications

Susanne Saussele

2 joint publications

Jane F Apperley

2 joint publications

Koji Sasaki